Micreos secures EUR 12M

Antibiotic play Micreos B.V. (Wageningen, the Netherlands) said it raised EUR 12 million ($13.4 million) from undisclosed equity investors.

Micreos develops bacteriophage-derived lysins that kill bacteria selectively and are not prone to inducing antibiotic resistance. CEO Mark Offerhaus told BioCentury Micreos would use the funds to support development of Staphefekt, a bacteria-killing enzyme specific to Staphylococcus aureus, to treat recurrent skin infections and chronic wounds associated with S. aureus infection. Micreos already markets a formulation of Staphefekt to treat S. aureus and methicillin-resistant S. aureus (MRSA) skin infections on intact skin (see BioCentury Innovations, Dec. 11, 2014). ...